Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice

Neuropharmacology

Volumn 38, Issue 4, 1999, Pages 555-565

  Boulay, D ^a   Depoortere, R ^a   Rostene, W ^b   Perrault, G ^a   Sanger, D J ^a  

^a SANOFI   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

7 OH DPAT; Core temperature; Dopamine D3 receptor; Knock out mice; Locomotor activity; PD 128907; PNU 99194A; Quinelorane

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; QUINELORANE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; (5,6 DIMETHOXYINDAN 2 YL)DIPROPYLAMINE; (5,6-DIMETHOXYINDAN-2-YL)DIPROPYLAMINE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H (1)BENZOPYRANO(4,3 B) 1,4 OXAZIN 9 OL; 3,4,4A,10B-TETRAHYDRO-4-PROPYL-2H,5H-(1)BENZOPYRANO(4,3-B)-1,4-OXAZIN-9-OL; 7 HYDROXY 2 N,N DIPROPYLAMINOTETRALIN; 7-HYDROXY-2-N,N-DIPROPYLAMINOTETRALIN; BENZOPYRAN DERIVATIVE; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, MOUSE; INDAN DERIVATIVE; OXAZINE DERIVATIVE; QUINOLINE DERIVATIVE; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; FEMALE; GENOTYPE; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CIRCADIAN RHYTHM; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; MOTOR ACTIVITY; MOUSE MUTANT;

ANIMALS; BENZOPYRANS; BODY TEMPERATURE; CIRCADIAN RHYTHM; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; INDANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; OXAZINES; QUINOLINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDRONAPHTHALENES;

EID: 0032586853     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00213-5     Document Type: Article

References (33)

1. Accili D., Fishburn C.S., Drago J., Lachowicz J.E., Steiner H., Park B.-H., Gauda E.B., Lee E.J., Cool M.H., Gerfen C.R., Sibley D.R., Westphal H., Fuchs S. D3 dopamine receptor knock-out mice. Society for Neuroscience. 21:1995;149.5.
2. 3 dopamine receptor gene is associated with hyperactivity in mice. Proceeding of National Academy of Sciences USA. 93:1996;1945-1949.
3. Baik J.-H., Picetti R., Salardi A., Thiriet G., Dierich A., Depaulis A., Le Meur M., Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 377:1995;424-428.
4. 3 receptor test in vitro predicts decreased cocaine self-administration in rats. NeuroReport. 8:1997;2373-2377.
5. 3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology. 136:1998;284-290.
6. 2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self-administration in rats, Psychopharmacology, in press.
7. Crusio W.E. Gene-targeting studies: new methods, old problems-commentary. Trends in Neurosciences. 19:1996;186-187.
8. 3 receptor antagonist PNU 99194A on motor behavior and emotional reactivity in C57BL/6J mice. European Journal of Pharmacology. 337:1997;147-155.
9. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends in Neurosciences. 19:1996;177-182.
10. Jose P.A., Drago J., Accili D., Eisner G.M., Felder R.A. Transgenic mice to study the role of dopamine receptors in cardiovascular function. Clinical and Experimental Hypertension. 19:1997;15-25.
11. 2-receptor-deficient mice. Society for Neuroscience. 23:1997;270.1.
12. Koeltzow T.E., Cooper D.C., Hu X.-T., Xu M., Tonegawa S., White F.J. In vivo effects of dopaminergic ligands in dopamine D3 receptor deficient mice. Society for Neuroscience. 21:1995;149.3.
13. 3 receptor mutant mice. The Journal of Neuroscience. 18:1998;2231-2238.
14. 3 receptor binding affinities. European Journal of Pharmacology. 277:1995;209-214.
15. Lathe R. Mice, gene targeting and behaviour: more than just genetic background. Trends in Neurosciences. 19:1996;183-186.
16. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacological Reviews. 49:1997;231-252.
17. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proceedings of the National Academy of Sciences USA. 89:1992;8155-8159.
18. Meller E., Hizami R., Kreuter L. Hypothermia in mice: D2 dopamine receptor mediation and absence of spare receptors. Pharmacology, Biochemistry and Behavior. 32:1989;141-145.
19. 2 receptors elicits prolactin secretion and catalepsy. Journal of Pharmacology and Experimental Therapeutics. 275:1995;885-898.
20. Perrault Gh., Depoortere R., Sanger D.J. Hypothermia and climbing behaviour induced by D2/D3 dopamine agonists in mice. Behavioural Pharmacology. 7(1):1996;83.
21. Pugsley T.A., Davis M.D., Akunne H.C., Mackenzie R.G., Shih Y.H., Damsma G., Wikstrom H., Whetzel S.Z., Georgic L.M., Cooke L.W., Demattos S.B., Corbin A.E., Glase S.A., Wise L.D., Dijkstra D., Heffner T.G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. Journal of Pharmacology and Experimental Therapeutics. 275:1995;1355-1366.
22. Sanger D.J., Depoortere R., Perrault Gh. Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behavioural Pharmacology. 7:1996;477-482.
23. 3 receptors. Psychopharmacology. 130:1997;387-395.
24. Sautel F., Griffon N., Levesque D., Pilon C., Schwartz J.-C., Sokoloff P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. NeuroReport. 6:1995;329-332.
25. 3 receptor and its relevance in psychiatry. International Clinical Psychopharmacology. 10:1995;15-20.
26. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
27. 2 receptor. European Journal of Pharmacology. 225:1992;331-337.
28. 3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiology and Behavior. 63:1998;137-141.
29. Varty G.B., Higgins G.A. Investigations into the nature of a 7-OH-DPAT discriminative cue: comparison with D-amphetamine. European Journal of Pharmacology. 339:1997;101-107.
30. Varty G.B., Higgins G.A. Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? Behavioural Pharmacology. 9:1998;445-455.
31. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. Journal of Neural Transmission [Gen Sect]. 94:1993;11-19.
32. Xu M., Caine S.B., Cooper D.C., Gold L.H., Graybiel A.M., Hu X.T., Koeltzow T.E., Koob G.F., Moratalla R., White F.J., Tonegawa S. Analyses of dopamine D3 and D1 receptor mutant mice. Society for Neuroscience. 21:1995;149.2.
33. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.-T., White N.M., Graybiel A.M., White F.J., Tonegawa S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 19:1997;837-848.